Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder

NCT06673368 is registered in ClinicalTrials.gov with Neurocentria, Inc. as lead sponsor.

NCT NCT06673368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06673368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder
Lead sponsor
Neurocentria, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
February 25, 2025
Completion date
July 15, 2025
Enrollment
2 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

adhd